Novavax Expects to File for Covid-19 Vaccine Approval in December as 2nd Trial Begins

Novavax, Inc. CEO Stanley Erck is expecting to file for Covid-19 vaccine approval in the U.S. by December, reported Czech daily Hospodarske Noviny on Thursday.

 

The production is expected to be at Novavax’s plant in Czech, which would give the country access to the vaccine once approved.

Earlier on Monday, Novavax were enrolling volunteers for the second phase of its ongoing clinical trial for Covid-19 vaccine. The interim data is expected to be published in the fourth quarter this year.